Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01232946 · ClinicalTrials.gov registry record · NA

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

A NA study, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT01232946: Completed NA study, sponsored by Indiana University.

NCT01232946 is a NA study that has completed, run by Indiana University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01232946, a NA study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).

Primary Outcome

PET measurements of myocardial glucose uptake will be done after 3 months of exposure to liraglutide, insulin detemir, or liraglutide plus insulin detemir

Interventions

  • DRUG liraglutide
  • DRUG insulin detemir
  • DRUG liraglutide plus insulin detemir

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2012-01
Est. Completion 2017-09-08
Phase NA
Indiana University

890 total trials

What the finished NCT01232946 record still lists

NCT01232946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 3 interventions - of which liraglutide is the first listed.

NCT01232946 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01232946 about?

NCT01232946 is a clinical study titled "Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake". 27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 20...

What is the current status of trial NCT01232946?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2012-01. Estimated completion is 2017-09-08.

What interventions are being tested in trial NCT01232946?

The interventions under investigation include: liraglutide (DRUG), insulin detemir (DRUG), liraglutide plus insulin detemir (DRUG).

Who is sponsoring clinical trial NCT01232946?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01232946's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01232946, the US trial registry maintained by the National Library of Medicine. NCT01232946 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.